FDA Drug Recalls
1,525 recalls · Class III, newest first
Cystaran (cysteamine ophthalmic solution)
Subpotent drug: Out of specification for an active ingredient cysteamine hydrochloride.
Triamterene and Hydrochlorothiazide Tablets
Cross Contamination With Other Products: presence of unrelated ingredients (i.e. traces of Lisinopril, Mannitol, Iron, Calcium and Phosphorous).
24-HOUR Oral Care q4 Kit with Ballard* Technology
Subpotent Drug: Product crystallization with accompanying low out of specification results for chlorhexidine assay.
24-HOUR Oral Care q2 Kit with Ballard* Technology
Subpotent Drug: Product crystallization with accompanying low out of specification results for chlorhexidine assay.
Chlorhexidine Gluconate Oral Rinse
Subpotent Drug: Product crystallization with accompanying low out of specification results for chlorhexidine assay.
Fabior (tazarotene)
Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.
Tramadol Hydrochloride 50 mg tablets
Labeling: Incorrect or Missing Lot and/or Exp Date
Indomethacin Capsules USP
Labeling: Incorrect Instructions: bottles incorrectly labeled with the usual adult dosage of "One or two capsules 2 or 3 times a day." rather than the correct usual adult dosage of "One capsule 2 or 3 times a day.
buPROPion HCl Extended-Release Tablets
Failed Dissolution Specifications; during stability testing
buPROPion HCl Extended-Release Tablets
Failed Dissolution Specifications; during stability testing
Triamcinolone Acetonide Lotion
Failed Impurities/Degradation Specifications: High out of specification results for an impurity.
Psoriasin Daytime Relief Cream with Vitamin D & Oatmeal
Subpotent Drug: The product has failed to maintain its label claim of coal tar throughout its labeled 24-month expiry period.
Clocortolone Pivalate Cream
Failed Stability Specifications:Out-of-specification results observed for viscosity during stability testing.
Decitabine for Injection
Failed impurities/degradation specifications: Failure to water content and impurity
Brilliant Blue G for Intraocular Injection 0.5mL vial 0.25 mg/mL…
Labeling: Label Mix-Up: Brilliant Blue G was labeled with an inaccurate auxiliary label which contained active/inactive ingredient information for incorrect product.
Lupin Hydrocodone Bitartrate and Homatropine Methylbromide Tablets
Failed Impurities/Degradation Specifications
Flucanazole Injection
Superpotent and Failed Stability Specifications; out of specification results for assay and water vapor permeability
Methylphenidate Hydrochloride Extended-release Tablets
Subpotent Drug:100-count product bottle labeled as Methylphenidate HCL ER Tablets 36 mg found to contain 1 27 mg Methylphenidate HCL ER Tablet.
Lynparza (olaparib)
Failed Impurities/Degradation Specifications; elevated levels of quality attribute Form L (polymorph).
labetalol HCl injection 20 mg/4 mL
Labeling; Incorrect or Missing Lot number/Expiration Date; some product labels incorrectly indicates a compounding date of 12/27/2018 and use-by date of 03/27/2019 instead of 12/27/2017 and use-by-date of 03/27/2018
Atropine Sulfate Ophthalmic 1% Solution
Failed Stability Specification: OOS low viscosity results discovered during retain testing.
Cystaran (cysteamine ophthalmic solution)
Subpotent Drug: Out of specification for an active ingredient cysteamine hydrochloride.
Calcium Acetate Capsules
Presence of Foreign Tablets/Capsules
BonaDur For Men
CGMP Deviations: not manufactured according to current good manufacturing practices.